Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report)’s stock price fell 21.1% on Thursday . The company traded as low as $0.6204 and last traded at $0.65. Approximately 110,106 shares changed hands during trading, a decline of 93% from the average session volume of 1,521,488 shares. The stock had previously closed at $0.8236.
Qualigen Therapeutics Stock Down 21.1%
The firm’s fifty day simple moving average is $1.13 and its 200-day simple moving average is $1.35. The firm has a market capitalization of $1.10 million, a PE ratio of -0.09 and a beta of 0.24.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.
Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories.
See Also
- Five stocks we like better than Qualigen Therapeutics
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
